( NASDAQ-NMS:BPAX )

News from ceregene, inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

May 21, 2013, 07:00 ET Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study

Ceregene, Inc. today announced additional efficacy data from a secondary analysis of its double-blind, randomized, controlled Phase 2b clinical...


Apr 19, 2013, 14:00 ET Ceregene Reports Data From Parkinson's Disease Phase 2b Study

Ceregene, Inc. today announced the top-line data from its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin),...


Mar 13, 2013, 07:00 ET Ceregene And Alzheimer's Disease Cooperative Study Group Complete Enrollment Of CERE-110 Phase 2 Trial

Ceregene, Inc. today announced the completion of enrollment in its double-blind Phase 2 clinical study of CERE-110 (AAV-NGF), a gene therapy...


May 17, 2012, 07:00 ET Ceregene Parkinson's Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)

Ceregene Inc., a biotechnology company developing treatments for neurodegenerative diseases such as Parkinson's disease, will present new data...


Dec 01, 2011, 07:00 ET Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinson's Disease

 Ceregene, Inc. reported today that it has completed enrollment in its Phase 2b trial of CERE-120, a gene therapy product expressing the...


Feb 15, 2011, 07:00 ET Ceregene Reports New Findings Regarding How Parkinson's Brains Respond to Neurotrophic Factors

Ceregene, Inc., a biopharmaceutical company, reported today that its scientists and collaborators have published new experimental findings in...


Feb 03, 2011, 09:00 ET Ceregene Advances Phase 2b CERE-120 (AAV2-neurturin) Trial in Parkinson's Disease

Ceregene, Inc., a biopharmaceutical company, announced today that it is progressing with enrollment and dosing in its CERE-120 (AAV2-neurturin)...


Nov 11, 2010, 07:00 ET Ceregene Raises $11.5 Million in Series D Financing

Ceregene, Inc., a biopharmaceutical company, announced today that it has closed its Series D preferred financing in the amount of $11.5 million....


Oct 19, 2010, 12:26 ET Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinson's Disease

Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study...


Apr 28, 2010, 07:00 ET Ceregene has Initiated a New Phase 1/2 Trial Of CERE-120 for Parkinson's Disease

Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a...


Aug 05, 2009, 09:00 ET Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients

Ceregene, Inc. today announced that the Michael J. Fox Foundation will provide partial funds for long-term follow-up testing of patients...


May 27, 2009, 07:00 ET Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease

-- Longer term follow-up indicates modest efficacy in primary and related endpoints -- Ceregene, Inc. today reported additional clinical...


Nov 26, 2008, 09:15 ET Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease

Ceregene, Inc., a biopharmaceutical company, today reported clinical data from a double-blind, controlled Phase 2 trial of CERE-120 in 58 patients...


Nov 04, 2008, 09:00 ET Ceregene Phase 2 Clinical Trial for Alzheimer's Disease to be Funded by $5.4 Million Grant From National Institutes of Health

Ceregene, Inc., a biopharmaceutical company, today announced that the University of California, San Diego (UCSD) has received a $5.4 million grant...


Apr 23, 2008, 01:00 ET Ceregene Announces Two Key Additions to Leadership Team

SAN DIEGO, April 23 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, today announced that it has added two key people to its...


Jan 07, 2008, 00:00 ET Ceregene to Present at JPMorgan 26th Annual Healthcare Conference

SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/ -- Ceregene, Inc. today announced that Jeffrey M. Ostrove, Ph.D., president and chief executive...


Dec 06, 2007, 00:00 ET Ceregene Promotes Dr. Raymond Bartus to Executive Vice President

SAN DIEGO, Dec. 6 /PRNewswire/ -- Ceregene, Inc. today announced the promotion of Raymond T. Bartus, Ph.D., to the position of executive vice...


Sep 21, 2005, 01:00 ET Ceregene Reports Initiation of Phase 1 Clinical Trial of Novel Gene Therapy for Patients With Parkinson's Disease

SAN DIEGO, Sept. 21 /PRNewswire-FirstCall/ -- Ceregene announced today that patient treatment is underway in its Phase I study of CERE-120 to...


Jul 12, 2005, 01:00 ET Ceregene Adds Biotech Executive John Walker to Its Board of Directors

SAN DIEGO, July 12 /PRNewswire-FirstCall/ -- Ceregene, Inc. announced today that it has expanded its Board of Directors to 7 members with the...


Apr 25, 2005, 01:00 ET Ceregene Scientific Co-Founder Publishes Alzheimer's Disease Clinical Trial Results in Nature Medicine

SAN DIEGO, Calif., April 25 /PRNewswire/ -- Ceregene, Inc. scientific co- founder, Mark Tuszynski M.D., Ph.D., published today in the May 2005...


Feb 09, 2005, 00:00 ET Ceregene Promotes Raymond Bartus to Senior Vice President and Chief Operating Officer

SAN DIEGO, Feb. 9 /PRNewswire/ -- Ceregene Inc. announced the promotion of Raymond T. Bartus, Ph.D. to senior vice president and chief operating...


Dec 07, 2004, 00:00 ET Ceregene Expands Clinical Team With the Addition of Matt Kurth and Dan Lee

SAN DIEGO, Dec. 7 /PRNewswire-FirstCall/ -- Ceregene, Inc. today announced that it has expanded its clinical team with the appointment of...


Sep 21, 2004, 01:00 ET Ceregene Begins Phase I Clinical Trial of Novel Gene Therapy Product for Patients With Alzheimer's Disease

SAN DIEGO, Sept. 21 /PRNewswire-FirstCall/ -- Ceregene, Inc., a biotechnology company focused on gene therapies for neurodegenerative disorders,...


Aug 04, 2004, 01:00 ET Ceregene Announces $32 Million Series B Financing

SAN DIEGO, Aug. 4 /PRNewswire-FirstCall/ -- Ceregene, Inc., a biotechnology company focused on the treatment of neurodegenerative disorders...


Apr 29, 2004, 01:00 ET Ceregene Confirms Plans to Further Develop Alzheimer's Disease Gene Therapy

SAN DIEGO, April 29 /PRNewswire/ -- Ceregene, Inc., today announced that based on preliminary findings in a study conducted at the University of...